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Overexpression of suppressor of zest 
12 is associated with cervical node metastasis 
and unfavorable prognosis in tongue squamous 
cell carcinoma
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Yanling Wang1 and Jie Cheng1,2*
Abstract 
Objective: Increased expression of suppressor of zest 12 (SUZ12), a core component of the polycomb repressive 
complex 2, contributes to human tumorigenesis and associates with patient prognosis. In the present study, we 
sought to investigate the expression of SUZ12 and its clinicopathological significance in primary tongue squamous 
cell carcinoma (TSCC).
Methods: The expression of SUZ12 protein was determined by immunohistochemistry in clinical samples from a 
retrospective cohort of 72 patients with primary TSCC who were treated at our institution from Jan. 2007 to Dec. 2013. 
The potential associations between SUZ12 abundance and multiple clinicopathological parameters were assessed by 
Chi square test. Moreover, the effect of SUZ12 expression on patients’ survival was further estimated by Kaplan–Meier 
and Cox regression analyses.
Results: Our immunohistochemical staining data revealed aberrant overexpression of SUZ12 in a large subset of 
TSCC as compared to normal tongue mucosa. Elevated SUZ12 was found to be significantly associated with cervical 
nodes metastasis (P = 0.0325) and reduced overall as well as disease-free survival (Log-rank test, P = 0.0225, 0.0179, 
respectively). Both univariate and multivariate Cox regression analysis identified the expression status of SUZ12 (low/
high) as an important independent prognostic factor for patients’ survival.
Conclusions: Our data reveal that aberrant SUZ12 overexpression is associated with cervical nodes metastasis and 
reduced survival in TSCC. These findings suggest that SUZ12 might play critical roles during tongue tumorigenesis 
and serve as a novel biomarker with diagnostic and prognostic significance.
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Background
Oral cancer is one of the most common solid malignancy 
worldwide, accounting for approximately 3% of all malig-
nancies in both sexes. Several etiologic risks including 
human papillomavirus infection, smoking, and heavy 
alcohol consumption have been increasingly recognized 
for oral carcinogenesis [1, 2]. The overweighing major-
ity of oral cancer is classified as squamous cell carcinoma 
(SCC) and mostly arises from tongue followed by mouth 
floor, buccal as well as gingiva [1, 2]. Thus, tongue SCC 
(TSCC) is a representative cancer subtype of OSCC and 
accounts for a large fraction of OSCC cases. The past dec-
ades have witnessed tremendous progress in multi-modal 
therapy against TSCC. However, the long-term survival 
for patients with TSCC is not markedly improved, espe-
cially for those with advanced diseases [3]. These facts 
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underscore the highly aggressive nature of TSCC and 
the unresolved challenge for diagnostic and therapeutic 
management of this malignancy in the clinic. Until now, 
few biomarkers have been equivocally established for 
diagnostic and prognostic management of tongue cancer. 
Therefore, the identification of the new biomarkers and 
therapeutic targets for TSCC is paramount and urgent 
for clinicians to improve the patients’ prognosis.
Epigenetic abnormality is a hallmark of human cancer 
and greatly contributes to cancer initiation and progres-
sion [4]. Mounting evidence has established that several 
epigenetic modulators have been identified as key media-
tors driving tumorigenesis by serving as pro-oncogenes 
or tumor suppressor genes. Moreover, these epigenetic 
modulators hold great promise as putative therapeutic 
targets against cancer largely owing to their pervasive 
roles in gene regulation as well as the inherent reversible 
nature of epigenetic alternations [5]. Among these epige-
netic modulators underlying tumorigenesis, several mem-
bers of polycomb group (PcG) proteins have stood out 
as essential participators of malignant transformation as 
well as promising targets for cancer therapeutic interven-
tion. Previous studies have revealed that the PcG compo-
nents usually assemble in stable multi-protein complexes 
together with additional factors to maintain their target 
genes in a transcriptionally repressive state [6]. In brief, 
two polycomb repressive complexes (PRC1 and PRC2) 
harbor multiple core members to execute their functions 
by histone modifications and in turn induce gene silenc-
ing [7]. Our previous studies and others have offered 
strong evidence that multiple members of PcG such as 
Bmi1 and EZH2 are bona fide oncogenes contributing 
to tumorigenesis in diverse sites throughout the whole 
body including tongue and their overexpression associ-
ates with cancer aggressiveness and poor prognosis in a 
broad spectrum of human cancer including tongue cancer 
[8–10]. Notably, suppressor of zest 12 (SUZ12) is one of 
the core component of PRC2, which is essential for PRC2-
mediated gene silencing by generating trimethylation on 
lysine 27 residue of histone H3 (H3K27me3) [11]. How-
ever, the biological roles and associated molecular mecha-
nisms of SUZ12 underlying tumor development are just 
beginning to be elucidated. For example, SUZ12 has been 
found to be frequently overexpressed in several solid can-
cers including colorectal, ovarian and non-small lung can-
cer, etc. [12–14]. Furthermore, its aberrant overexpression 
commonly associated with tumor aggressive behaviors, 
advanced clinicopathological features and decreased 
survival, thus suggesting potential roles of SUZ12 as a 
novel cancer biomarker and a putative oncogene [12–14]. 
However, to the best of our knowledge, the expression of 
SUZ12 and its clinicopathological significance in TSCC 
have not been established yet.
Herein, we sought to investigate the expression of 
SUZ12 protein in primary human TSCC specimens and 
identify potential relationship between its abundance and 
clinicopathological features as well as patients’ survival.
Methods
Patients and tissue specimens
A retrospective cohort of 72 patients with primary 
TSCC treated at our institution between Jan. 2007 and 
Dec. 2013 were enrolled. Written informed consent was 
obtained from these patients. Patient inclusion criteria 
were described as follows: (1) primary TSCC without 
any prior history of surgery, chemotherapy or radiother-
apy; (2) patients underwent radical tumor resection and 
neck dissection (elective or therapeutic neck dissection 
as required); (3) detailed information available including 
epidemiologic, clinical, pathological and follow-up data. 
The archived tissue samples were retrieved and haema-
toxylin–eosin staining slides for each patient were further 
analyzed to confirm the previous diagnose based on the 
established histopathological criteria. Fifteen samples of 
healthy tongue mucosa were obtained from other non-
cancer surgeries and histologically confirmed under 
microscope by senior oral pathologists. This study pro-
tocol was reviewed and approved by the Research Ethic 
Committee of Nanjing Medical University (2015-0126).
Histopathological evaluation, clinicopathological 
categorization and immunohistochemical staining 
of SUZ12
The relevant clinicopathological parameters for each case 
including histological grade, TNM classification, clini-
cal stage, etc. were determined similarly as we described 
before [8, 9, 15]. Immunohistochemical staining for 
SUZ12 was performed on 4-µm formalin-fixed, paraffin-
embedded specimens using routine procedure. Briefly, 
tissue sections from representative paraffin blocks were 
deparaffinised in xylene and rehydrate through graded 
alcohols. Tissue slides were then processed in microwave 
heating in 10 mM citrate buffer (pH 6.0) for 15 min for 
antigen retrieval and 3% hydrogen peroxide for endog-
enous peroxidase inactivation. These sections were fur-
ther incubated with primary antibody (anti-SUZ12, 
1:200 dilution; Abcam, ab12073, USA) at 4  °C overnight 
and developed with 3.3′-diaminobenzidine and coun-
terstained with haematoxylin. The immunoreactivity in 
each slide was assessed independently by two senior oral 
pathologists without knowledge about the relevant clini-
cal and pathological data. Negative controls (without pri-
mary antibody incubation) were included in each staining 
run. Immunoreactivity was semi-quantitatively evaluated 
according to staining intensity and distribution using the 
immunoreactive score which was calculated as intensity 
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score  ×  proportion score as we reported previously 
[8, 15, 16]. Intensity score was defined as 0, negative; 1, 
weak; 2, moderate; 3, strong. The proportion score was 
defined as 0, negative; 1, <10%; 2, 11–50%; 3, 51–80%; 
4, >80% positive cells. Therefore, the total score ranged 
from 0 to 12. Accordingly, the immunoreactivity of each 
slide was categorized into three subgroups based on the 
final score: 0, negative; 1–4, low expression; 4–12, high 
expression, similar as our previous reports [8, 15, 16].
Statistical analyses
The associations between SUZ12 expression and various 
clinicopathological parameters of patients were evalu-
ated using Chi square test. The survival rates of patients 
were estimated using Kaplan–Meier method and com-
pared with Log-rank test. The prognostic analyses were 
performed by univariate and multivariate Cox regression 
models to determine the individual clinicopathological 
variables with patients’ overall or disease-free survival. 
P values <0.05 (two-sided) were considered statistically 
significant. All statistical analyses were performed using 
Graphpad Prism 5 (La Jolla, CA, USA) or SPSS 18.0 
(Armonk, NY, USA).
Results
Clinicopathological characteristics and SUZ12 expression 
in primary TSCC
Previous studies have provided clues to support the 
notion that SUZ12 is usually overexpressed in sev-
eral human cancers and might serve as a putative pro-
oncogene associated with tumorigenesis [12, 13]. To 
examine SUZ12 expression in TSCC, we evaluated the 
expression levels of SUZ12 protein by immunohisto-
chemical staining in a retrospective cohort of 72 primary 
TSCC samples. The epidemiologic information and rel-
evant clinicopathological features (age, gender, smok-
ing, alcohol use, pathological grade, tumor size, clinical 
stage, cervical node status) of these patients included 
were summarized in Table  1. In brief, 40 male and 32 
female patients were enrolled with mean age 56.5  years 
(31–81  years). The follow-up period ranged from 28 
to 95  months with average 52.8  months. Based on our 
immunohistochemistry scoring regime, SUZ12 protein 
abundance in these primary TSCC and normal tongue 
epithelial samples (n = 15) was categorized, respectively. 
As shown in Table 2, SUZ12 levels in TSCC samples were 
graded as negative (4), low (31) and high (37) expression, 
respectively. In parallel, its expression levels in their nor-
mal counterparts were divided into negative (5), low (7) 
and high (3), respectively. These data showed significant 
difference of SUZ12 expression pattern between TSCC 
and normal tongue mucosa, and also clearly indicated 
that SUZ12 was aberrantly overexpressed in a significant 
fraction of primary TSCC. The representative immuno-
histochemical staining of SUZ12 in TSCC and normal 
tongue mucosa was shown in Fig. 1. High SUZ12 expres-
sion was mainly identified in the nucleus and much less 
in the cytoplasm in cancer cells, whereas weak stain-
ing was observed in normal tongue epithelial cells. The 
detailed associations between SUZ12 expression and 
clinicopathological variables were further analyzed and 
shown in Table 1. There were no significant correlations 
between SUZ12 expression with patients’ gender, age, 
smoking, alcohol use, tumor size, pathological grade and 
clinical stage. However, significant association between 
SUZ12 abundance with cervical nodes metastasis was 
found with P value 0.0325 (Chi square test).  
SUZ12 expression associates with TSCC patients’ survival
To reveal the potential prognostic value of SUZ12 expres-
sion in TSCC, we then attempted to evaluate the correla-
tion between SUZ12 expression and patients’ survival. 
Table 1 The associations between  SUZ12 expression 
and  multiple clinicopathological parameters in  primary 
TSCC
The number in italic indicate statistical significance with p values <0.05
a Both of patients with low and negative SUZ12 staining are stratified into low 
SUZ12 category for simplicity
Clinicopathological  
parameters
Cases SUZ12 P values
Lowa High
Gender 35 37 0.486
 Male 40 21 19
 Female 32 14 18
Age
 ≤60 40 17 23 0.3429
 >60 32 18 14
Smoking
 No 37 19 18 0.6324
 Yes 35 16 19
Alcohol use
 No 40 22 18 0.2253
 Yes 32 13 19
Tumor size
 T1–T2 58 29 29 0.7683
 T3–T4 14 6 8
Pathological grade
 I 32 19 13 0.1542
 II–III 40 16 24
Cervical node metastasis
 N(0) 38 23 15 0.0325
 N(+) 34 12 22
Clinical stage
 I–II 36 21 15 0.1567
 III–IV 36 14 22
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Until the last follow-up, 41 of 72 (56.9%) patients were 
alive and disease-free, 6 (8.3%) patients alive but with 
recurrence and/or cervical nodal metastases, 25 (34.7%) 
patients dying due to local recurrence, metastases, or other 
unrelated diseases. The results from Kaplan–Meier sur-
vival analyses indicated that high SUZ12 expression had an 
adverse prognostic impact on patients’ outcomes. In detail, 
as shown in Fig.  2, high SUZ12 abundance significantly 
associated with reduced overall survival and disease-free 
survival (Log-rank, P = 0.0225, 0.0179, respectively).
To further assess the clinical significance of SUZ12 
expression as a prognostic predictor for patients with 
TSCC, the univariate and multivariate survival analyses 
(Cox proportional hazards regression model) were per-
formed. As indicated in Table  3, the univariate survival 
analysis revealed that SUZ12 expression status and cer-
vical node metastasis were significantly associated with 
overall survival (hazard ratio [HR] 3.023; 95% confidence 
interval [95% CI] 1.216–7.516; P = 0.017 for SUZ12; HR 
1.759; 95% CI 1.240–3.291; P =  0.042 for cervical node 
metastasis, respectively), while other clinicopathological 
variable didn’t reach the statistical significance. To rule 
out the confounding factors, multivariate survival analy-
sis was performed. In this Cox regression model, only the 
SUZ12 expression status was identified as an independ-
ent prognostic marker for the overall survival of patients 
with TSCC (HR 2.848; 95% CI 1.121–7.240; P = 0.028).
Discussion
The epigenetic modifiers, PRC1 and 2, regulate gene 
expression by modifying chromatin structure and are 
intricately implicated in various biological and pathologi-
cal processes including stem cell plasticity, cell differen-
tiation and proliferation as well as tumorigenesis [6, 17, 
Table 2 SUZ12 expression patterns in  TSCC and  normal 
tongue mucosa
The number in italic indicate statistical significance with p values <0.05
SUZ12 expression P values
Negative Low High
Normal tongue mucosa 5 7 3 0.0025
TSCC 4 31 37
Fig. 1 Immunohistochemical staining of SUZ12 in TSCC specimens and normal tongue mucosa. a Representative weak staining of SUZ12 (low 
expression) in normal human tongue mucosa (×200). Nuclei are counterstained with haematoxylin. b Representative weak staining of SUZ12 (low 
expression) in primary TSCC sample (×200). c Representative strong staining of SUZ12 (high expression) in primary TSCC sample (×200). d This 
image is magnified from the black box area in c (×400). SUZ12 expression is identified primarily in nuclei of cancer cells. Scale bar 100 μm
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18]. Previous studies have suggested that the SUZ12, one 
of the core components of PRC2, might be an oncogene 
driving tumorigenesis and serve as a novel diagnostic 
biomarker and therapeutic target for cancer treatment 
[13, 18, 19]. Herein we investigated the expression pat-
tern of SUZ12 in primary TSCC and determined its clin-
icopathological relevance and prognostic significance 
for patients with TSCC. Our findings reveal that SUZ12 
is aberrantly overexpressed in a significant fraction of 
TSCC and its overexpression associates with aggressive 
clinicopathological features and unfavorable prognosis.
Tongue tumorigenesis in human is characterized by 
multiple and consecutive histopathological stages from 
normal epithelial to invasive SCC which is driven by 
oncogenes activation and tumor suppressor inactivation 
[2]. In particular, epigenetic inactivation of tumor sup-
pressor genes contributes to initiation and progression 
of tongue cancer [20]. Among them, these chromatin 
modifiers like the polycomb members have been increas-
ingly recognized as key players during tumorigenesis. 
They usually facilitate cancer initiation, overgrowth and 
metastasis, and also have been identified as therapeutic 
targets with remarkable translational potential [21]. We 
and others have provided evidence that several members 
of PcG such as EZH2 and Bmi1 are aberrantly upregu-
lated in tongue cancer and associated with aggressive-
ness and poor prognosis [8, 10]. Notably, highly elevated 
SUZ12 has been found in bladder, gastric, non-small cell 
lung and colorectal cancer, etc. [12, 13, 19]. In line with 
these previous finding, our data reveal that SUZ12 is 
significantly elevated in a large subset of human TSCC, 
thus supporting the notion that SUZ12 might be an bona 
fide oncogene fostering tumorigenesis in diverse sites 
throughout the body including tongue. To the best of 
our knowledge, this might be the first study to uncover 
the abnormal expression pattern of SUZ12 in TSCC. 
Fig. 2 Kaplan–Meier graphs representing the probability of TSCC patients’ survival based on SUZ12 expression status. a High SUZ12 expression is 
significantly associated with reduced overall survival in TSCC patients. P value from Log-rank test is shown. b High SUZ12 expression is significantly 
associated with reduced disease-free survival in TSCC patients. P value from Log-rank test is shown
Table 3 Univariate and multivariate survival analyses for patients with primary TSCC using proportional hazards meth-
ods
The numbers in italic indicate statistical significance with p values <0.05
a Both of patients with low and negative SUZ12 staining are stratified into low SUZ12 category for simplicity
Variable Univariate survival analysis Multivariate survival analysis
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Gender (male, female) 1.651 0.739–3.688 0.221 1.428 0.599–3.405 0.422
Age (≤60, >60) 0.753 0.338–1.680 0.489 1.374 0.601–3.141 0.452
Smoking (no, yes) 1.253 0.653–1.835 0.524 1.372 0.665–1.732 0.536
Alcohol use (no, yes) 1.121 0.547–1.538 0.753 1.231 0.557–1.861 0.643
Tumor size (T1–T2, T3–T4) 1.331 0.528–3.357 0.544 1.447 0.505–4.147 0.491
Pathological grade (I, II–III) 1.258 0.490–1.994 0.117 1.246 0.444–3.496 0.676
Cervical nodal metastasis (N0, N+) 1.759 1.240–3.291 0.042 1.696 1.104–3.067 0.056
Clinical stage (I–II, III–IV) 1.203 0.688–1.824 0.095 0.922 0.524–1.622 0.778
SUZ12 expression (lowa, high) 3.023 1.216–7.516 0.017 2.848 1.121–7.240 0.028
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However, due to the limited number of patients enrolled 
here, more number of patients from multiple institutions 
is needed to definitively establish the overexpression pat-
tern of SUZ12 as well as its diagnostic utility in tongue 
cancer.
Accumulating evidence has demonstrated that SUZ12 
overexpression significantly associated with aggressive-
ness in multiple human cancers [13]. For example, ele-
vated SUZ12 is significantly associated with tumor size, 
lymph node metastasis and clinical stages in non-small 
cell lung cancer and colorectal cancer [13, 14]. Similarly, 
our findings reveal that SUZ12 overexpression signifi-
cantly associates with cervical lymph nodes metastasis 
in TSCC, while the associations between other clinico-
pathological parameters and SUZ12 don’t reach statistical 
significance. Noticeably, Our findings and others point 
to an interesting link and positive association between 
SUZ12 expression and cancer metastasis irrespective of 
cancer origin and primary site [13, 22, 23]. Complemen-
tary to this notion, previous studies have demonstrated 
that the metastasis-regulator Snail recruits SUZ12 to the 
CDH1 promoter and represses E-cadherin expression, 
thus in turn triggers EMT and cancer metastasis [24, 
25]. Moreover, targeting SUZ12 by gene knockdown sup-
presses the migratory and invasive properties of cancer 
cells and inhibits tumor metastasis in animal models [13, 
25]. Taken together, we propose that SUZ12 is a novel 
cancer biomarker of TSCC which significantly associates 
with cervical node metastasis. It remains an interesting 
question to determine the expression level of SUZ12 in 
the metastatic lesions and its clinical significance, and 
further unravel its associated mechanistic underpins dur-
ing cancer metastatic spread.
The past decades have witnessed tremendous pro-
gress in diagnosis and treatment for TSCC. However, the 
5-year survival rate remains disappointing, suggesting 
that accurate prognostic prediction is a great challenge 
but highly beneficial in the clinic [3]. Previous stud-
ies have revealed that SUZ12 expression associates with 
patients’ prognosis and is identified as a key independent 
prognostic predictor for patients with epithelial ovar-
ian cancer, non-small cell lung cancer and gastric can-
cer [12, 13]. For example, Li et al. [12] have reported that 
expression of SUZ12 positively correlates with Ki67 and 
predicts shorter overall survival in patients with ovarian 
cancer. Consistent with these findings, our results indi-
cate that patients with high SUZ12 have significantly 
shorter survival as compared to those with low SUZ12. 
Furthermore, SUZ12 expression is identified as an inde-
pendent prognostic factor affecting survival of patients 
with TSCC. Thus, the expression status of SUZ12 might 
offer valuable information about patients’ prognosis and 
indication for effective follow-up management.
A line of evidence has uncovered that SUZ12 is criti-
cally involved in tumorigenesis by promoting cell pro-
liferation, migration and metastasis while suppressing 
apoptosis [12, 13, 25]. Moreover, SUZ12 together with 
miR-200b is important for cancer stem cell growth and 
invasive ability in breast cancer cells [26]. In particular, 
pharmacologic or genetic disruption of SUZ12 inhibited 
cell proliferation and invasion, and disrupted the mainte-
nance of cancer stem cell both in vitro and in vivo [12, 13, 
26, 27]. These abovementioned findings strongly suggest 
that SUZ12 serves as not only a novel cancer biomarker 
with diagnostic and prognostic values, but also a viable 
therapeutic target. Therefore, it remains an open and 
interesting question to unravel the roles of SUZ12 and its 
regulatory network during tongue tumorigenesis and to 
develop efficient approaches to therapeutically targeting 
SUZ12 in cancer.
Conclusions
In conclusion, our data reveal that SUZ12 is aber-
rantly overexpressed in a significant fraction of TSCC 
and might serve as a novel cancer biomarker as well as 
therapeutic target for tongue cancer. More studies are 
warranted to further unravel the mechanistic insights of 
SUZ12 dysregulation during the initiation and progres-
sion of TSCC.
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